Comparison of rhinitis treatments using MASK-air (R) data and considering the minimal important difference

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076416" target="_blank" >RIV/65269705:_____/22:00076416 - isvavai.cz</a>

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/10.1111/all.15371" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/all.15371</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/all.15371" target="_blank" >10.1111/all.15371</a>

Result language

angličtina

Original language name

Comparison of rhinitis treatments using MASK-air (R) data and considering the minimal important difference

Original language description

Background Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., &quot;real-world data&quot;). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods We assessed the MASK-air (R) app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30225 - Allergy

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Allergy

ISSN

0105-4538

e-ISSN

1398-9995

Volume of the periodical

77

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

3002-3014

UT code for WoS article

000809858900001

EID of the result in the Scopus database

2-s2.0-85131752144